ATIs engage toll-like receptor 4 (TLR-4) and release of pro-inflammatory cytokines in myeloid cells of both patients with CeD and non-diseased controls, as is expected for innate immune triggers. This evidence concerns the gene TLR4 and cranioectodermal dysplasia.